Sentences with phrase «by drug treatment»

The Perceptions of the Courts in Your Community Rottman and Hansen, Nat'l Ctr for State Courts (2000) This survey asked detailed questions of randomly selected individuals in an attempt to measure the public's reaction to the changing roles of judges and the courts exemplified by drug treatment and other problem - solving courts.

The researchers will also study possible side effects from the modulation of gut bacteria and FXR by drug treatment.

Pelvic floor exercises rank second, with 53 percent, followed by drug treatment, with 49 percent.

«Gambling distortions like the «near - miss» effect may be amenable to both psychological therapies for problem gambling, and also by drug treatments that may act on the underlying brain systems.

Not exact matches

The hep C treatment is being developed by the Drugs for Neglected Diseases Initiative (DNDi) in collaboration with Egyptian drug maker Pharco Pharmaceuticals.

But the initiative comes with another huge financial prize for firms that successfully win FDA approval for these niche therapies: a priority review voucher that can be used to slash the regulatory period for a different experimental specialty treatment being developed by a drug maker or, more often, sold for potentially hundreds of millions of dollars to another pharma company.

Dr. Nir Barzilai, the director of Institute for Aging Research at the Albert Einstein College of Medicine in New York, has been researching the drug, with the hopes of one day getting it approved as an anti-aging treatment by the FDA.

Pfizer's financial fortunes were boosted by strong demand for flagship drugs like Prevnar, the rheumatoid arthritis treatment Xeljanz, and the blood thinner Eliquis.

This drug has already staked its claim in the world of next - gen «checkpoint inhibitor» cancer treatments by besting rival Bristol - Myers Squibb's competing treatment Opdivo in advanced non-small cell lung cancer (NSCLC).

The memory - eating disease, expected to afflict 15 million Americans by 2060 (and tens of millions more around the world as life expectancy increases), has no cure; a new drug for the condition hasn't been approved in well over a decade; initially promising experimental treatments seem to be failing with clockwork regularity; and there's not even a definitive consensus on what, exactly, biopharma companies should focus on while developing Alzheimer's medicines.

But they've been hampered by somewhat skeptical physicians who still aren't sure that the drugs are worth their price (their topline costs are around $ 14,000 per treatment course); part of the problem is that it's unclear whether or not those dramatic cholesterol reductions actually translate into broader health outcomes like a reduced risk of stroke or heart attack in heart disease patients.

The companies have begun to market their «biosimilar» (a generic version of expensive biologic drugs) of Remicade — a copycat of J&J's best - selling rheumatoid arthritis and immunology treatment (which garnered more than $ 5 billion in U.S. sales last year) and was approved by the Food and Drug Administration (FDA) in April — at a striking 35 % discount to its list price.

Though hailed as «a new therapeutic principle» in 1990, it nonetheless took another eight years for the FDA to approve the first antisense drug, fomivirsen — for the treatment of AIDS - related retinitis caused by human cytomegalovirus.

Drugs like buprenorphine treat addiction, and naloxone reverses overdoses, but these treatments are often not covered by insurance providers.

That information — augmented by advocacy efforts from such Addyi supporters as the National Organization for Women and National Consumers League — turned the tide, and the FDA's joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee voted 18 to 6 to support approval for HSDD treatment, contingent on Sprout consenting to risk - mitigation measures like warnings and restrictions to prevent misuse.

The 32 - year - old CEO of Turing Pharmaceuticals became a target of widespread ire in September when he boosted the price of the toxoplasmosis treatment Daraprim by over 5,000 % after acquiring the drug in August.

Reldesemtiv has been granted orphan drug designation by the FDA for the potential treatment of spinal muscular atrophy.

In the quote provided by Sessions himself, he does not mention treatment, but instead offers the opinion that the drug prevention movement «was really so positive.»

Though it's not a perfect treatment, Eli Lilly's solanezumab — a drug 15 years in the making — will pass muster in clinical tests and be well on its way to FDA approval, as a therapy for mild Alzheimer's, by year's end.

And he built on that concept on Thursday, announcing that his firm will bolster its patient assistance programs for more than 40 drugs, including by helping people who make up to four times the federal poverty level buy their treatments for free.

Pfizer also came under fire over drug price increases including a record $ 107 million fine by U.K. regulators for hiking an epilepsy treatment's price by 2,600 %.

The new indication puts Kymriah in direct competition with Gilead Sciences» Yescarta, which was approved by the U.S. Food and Drug Administration in October for treatment of adults with diffuse large B - cell lymphoma who have failed to respond to other treatments.

PCSK9 inhibitors, the main ingredients in Amgen's Repatha and Sanofi and Regeneron's Praluent treatments, were first approved by the Food and Drug Administration in July 2015 for use by patients with a family history of high cholesterol or those who suffered high - cholesterol - induced heart attacks.

Klemp was approached about this potentially life - saving treatment by the original team involved in the drug's development.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Since biosimilars are so new to the U.S. market (there have been just five total approved here since 2015), it's been hard to gauge whether or not they can make a formidable dent in high drug prices by offering generic alternatives to branded treatments.

The drug known by the street names Ecstasy or Molly could be a promising treatment for post-traumatic stress disorder, according to a new study.

SRSE accounts for about 25,000 to 41,000 cases each year in the United States and there are currently no treatments approved by the U.S. Food and Drug Administration for the disorder, Sage said.

The U.S. Food and Drug Administration (FDA) is expected to decide by Nov. 29 whether to approve Kite's CAR T, axi - cel, for treatment of adults with advanced lymphoma.

Pharmacies in Chile's capital will start selling cannabis - based medicines this week, the first time such treatments have been offered by drug stores in Latin America.

Antares Pharma (ATRS)- The company possesses a strong pipeline of drug / device combination product candidates which provide better treatment options in a variety of disease settings - Xyosted could potentially be approved by September and should see significant adoption due to several advantages over current treatments (keep in mind global male hypogonadism market to exceed $ 3 billion within 10 years).

So far, its trials have shown it can improve outcomes when used alongside other multiple myeloma drugs and that could offer it some insulation if the market gets disrupted by new treatment approaches, such as gene therapy.

But the show has also done good, small - bore reporting on President Trump's domestic agenda — the impact on Kentucky drug - treatment programs if Obamacare is repealed, or how public - private partnerships, of the sort championed by Trump to rebuild infrastructure, have failed to work in building highways in Virginia.

InvivoSciences will continue to contribute to the improvement of human health by establishing a new paradigm for discovering drugs that focus on diseases with limited treatment options such as cardiac fibrosis, scleroderma, and lupus in a time - effective manner while remaining safe and cost effective.»

It is, in other words, one of the most toxic, dangerous, and potentially fatal drugs in the entire PDR, and it has been approved for use by the FDA only for the treatment of cancer — which is to say, the dangers of this drug are so massive that they are outweighed only by the benefit of abating or curing cancer.

For instance, most common adult solid tumors that are not cured by surgical removal are resistant to chemotherapy or radiation control, yet drug therapy is frequently offered as a «possibly effective» treatment because both patient and physician want to believe it so.

Only $ 700 million has been earmarked by the Bush administration for treatment, out of a total expenditure of $ 8 billion for the drug war.

But if the cancer treatment reduces cancer mortality by six percent, but the increase in death from suicide and drug and alcohol poisoning stays the same, then the overall death rate increases by two percent.

To wit, if a new cancer treatment reduces cancer mortality for a group by ten percent, but death from suicide and drug and alcohol abuse increases, say, by eight percent, then the overall death rate for the group goes down by two percent.

The Partnership at Drugfree.org mission to help parents prevent, intervene in and find treatment for drug and alcohol use by their children depends on donations from individuals, corporations, foundations and the public sector.

By accelerating promising drug candidates through the drug discovery and development pipeline and spearheading innovative public - private partnerships, we increase the chance of finding an effective treatment, and a cure, for Alzheimer's disease.

Clomiphene Citrate: A prescription drug typically usedfor the treatment of female infertility, it is taken by male athletes to negatethe effects of increased estrogen, a result of anabolic steroid abuse.

Treatments like fertility drugs primarily increase a person's odds of giving birth to fraternal twins (two eggs fertilized by two sperms).

I mentioned that what the drug was approved for, by the FDA, was for the treatment of ulcers.

scientific study has learneed that the benzodiazepine drug treatments, the actual Valiums along with Xanaxes, perform how they do by interesting any natural chemical called «gamma - aminobutyric acid, or even Gamma aminobutyric acid, therefore selling a relaxing impact in only exactly the same as the highly habit forming opioids.

For the purposes of this economic evaluation, the forms were initially used in a related study funded by the National Institute of Health Research (NIHR) research for patient benefit programme «assessing the impact of a new birth centre on choice and outcome of maternity care in an inner city area,» which will be reported in full elsewhere, comparing the costs of care in a free standing midwifery unit with care in an obstetric unit in the same trust.16 The data collected included details of staffing levels, treatments, surgeries, diagnostic imaging tests, scans, drugs, and other resource inputs associated with each stage of the pathway through intrapartum and after birth care.

HIV Medicine DOI: 10.1111/j.1468-1293.2011.00918.x IBFAN - Asia Position Statement on HIV and Infant Feeding, 13 October 2008 South African Tshwane Declaration on breastfeeding, S Afr J Clin Nutr 2011; 24 (4) UNAIDS 2010, Strategy Getting to Zero, UNAIDS Strategy 2011 — 2015 UNAIDS 2010, Agenda for Accelerated Country Action for Women, Girls, Gender Equality and HIV, 2010 - 2014 UNAIDS 2011, Countdown to Zero: Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive, 2011 - 2015 UNAIDS 2011 Press Release, 9 June, World leaders launch plan to eliminate new HIV infections among children by 2015 UNICEF Convention on the Rights of the Child UNICEF 2010, Facts for Life UNICEF 2011, Programming Guide, Infant and Young Child Feeding, 26 May 2011 WHO / UNICEF 2003, Global strategy for infant and young child feeding WHO 2007, Evidence on the long - term effects of breastfeeding: systematic reviews and meta - analysis WHO, UNAIDS, UNICEF 2009, Towards universal access: scaling up priority HIV / AIDS interventions in the health sector: progress report 2009 WHO 2009, Women and health, Today's evidence tomorrow's agenda WHO 2009, Acceptable medical reasons for use of breast - milk substitutes WHO 2009, Rapid advice: use of antiretroviral drugs for treating pregnant womenand preventing HIV Infection in infants WHO 2009, Rapid advice: revised WHO principles and recommendations on infant feeding in the context of HIV WHO 2010, Priority Interventions — HIV / AIDS prevention, treatment and care in the health sector WHO 2010, Guidelines on HIV and infant feeding: Principles and recomendations for infant feeding in the context of HIV and a summary of evidence WHO 2010, Annexure 7b to Guidelines on HIV and infant feeding.

In 1998, Dynamic Orthotic Cranioplasty ®, known as the DOC Band, became the first cranial helmet cleared by the U.S. Food and Drug Administration for plagiocephaly treatment and, a few years later, for plagiocephaly treatment associated with post-surgical correction.

The drug metformin is the most common treatment prescribed by health care providers for PCOS and is used to help women who experience difficulty both getting pregnant and maintaining a pregnancy.

Many steps in this misfired immune response are targeted by specific treatments such as systemic and biologic drugs.